Musings from The Power List: Peng Lu
September 4, 2026
Peng Lu argues that small molecules remain indispensable as AI transforms drug development
2 min read
False
Advertisement
Drug Discovery
How Glycosylation Is Shaping Cancer Biomarker Discovery
September 2, 2026
Glycosylation could offer cancer researchers a new way to understand tumors, identify biomarkers, and develop more precise therapies
3 min read
Phase III Success Marks Milestone for Personalized Cancer Vaccines
August 26, 2026
Merck and Moderna report positive phase III results for intismeran in melanoma, as The Medicine Maker revisits how cancer vaccines work and the challenges still facing the field
7 min read
Data Quality: Drug Discovery AI’s Indispensable Foundation
By Andrea Jacobs
August 25, 2026
Reliable discovery insights depend on models grounded in curated, verifiable scientific knowledge
5 min read
Musings from The Power List: Daniel Vitt
By Daniel Vitt
August 20, 2026
From multiple sclerosis to AI-driven discovery, Daniel Vitt reflects on the future of drug development
6 min read
Can Exosomes Unlock Nanomedicine’s Regenerative Medicine Potential?
August 12, 2026
NurExone CEO Lior Shaltiel discusses the company’s exosome-based approach to nerve regeneration, the manufacturing hurdles facing the field, and what it will take to bring nanotechnology therapeutics to patients
11 min read
Musings from The Power List: Ann Cleves
By Ann Cleeves
August 11, 2026
Ann Cleves on why the future of small-molecule drug discovery lies beyond the rule of five
3 min read
This Week’s CGT News: Gene-Editing Trial Death Raises Concerns
August 3, 2026
A previously undisclosed death in China raises questions about gene-editing oversight, deramiocel meets its Phase 3 Duchenne endpoint, and researchers identify a source of CAR NK dysfunction
4 min read
The Confidentiality Barrier to AI-Enabled Drug Development
By Timothy Pas, Laure Descamps
July 27, 2026
AI can help formulation teams better predict performance and allocate resources, but proprietary data protections remain a critical bottleneck
3 min read
Inside the Rise of circRNA
July 9, 2026
Circio CEO Erik Wiklund reflects on the discovery of human circular RNA and its evolution into a fast-moving therapeutic modality
11 min read
